StockMacro
Menu

Armata Pharmaceuticals

$3.03 -63% in 6 monthsMarket cap $112.7M

ARMP on XASE, Health Care, Armata Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 58% in a year while short interest reached 963K shares, 35 times its level a year earlier.

  • BadNet loss of $110.6M over 12 months and cash outflow of $26.9M
  • GoodInstitutional holders rose to 62 from 53 in the latest quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
61
Website
armatapharma.com
Listed
NYSE American, US
Last results
12 Nov 2026
Next results
expected around 24 Mar 2027 (an estimate: a year ago it reported on 25 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net income $54.9M.
Quarter to 31 Dec 2021: revenue –, net income -$6.0MQuarter to 31 Mar 2022: revenue –, net income -$8.8MQuarter to 30 Jun 2022: revenue –, net income -$9.2MQuarter to 30 Sep 2022: revenue –, net income -$8.6MQuarter to 31 Dec 2022: revenue –, net income -$10.3MQuarter to 31 Mar 2023: revenue –, net income -$14.5MQuarter to 30 Jun 2023: revenue –, net income -$3.5MQuarter to 30 Sep 2023: revenue –, net income -$31.2MQuarter to 31 Dec 2023: revenue –, net income -$19.8MQuarter to 31 Mar 2024: revenue –, net income -$25.0MQuarter to 30 Jun 2024: revenue –, net income $9.0MQuarter to 30 Sep 2024: revenue –, net income -$5.5MQuarter to 31 Dec 2024: revenue –, net income $2.6MQuarter to 31 Mar 2025: revenue –, net income -$6.5MQuarter to 30 Jun 2025: revenue –, net income -$16.3MQuarter to 30 Sep 2025: revenue –, net income -$26.7MQuarter to 31 Dec 2025: revenue –, net income -$124.3MQuarter to 31 Mar 2026: revenue –, net income -$115.3MQuarter to 30 Jun 2026: revenue –, net income $74.1MQuarter to 30 Sep 2026: revenue –, net income $54.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $124.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–$54.9M
30 Jun 2026–$74.1M
31 Mar 2026–-$115.3M
31 Dec 2025–-$124.3M
30 Sep 2025–-$26.7M
30 Jun 2025–-$16.3M
31 Mar 2025–-$6.5M
31 Dec 2024–$2.6M
30 Sep 2024–-$5.5M
30 Jun 2024–$9.0M
31 Mar 2024–-$25.0M
31 Dec 2023–-$19.8M
30 Sep 2023–-$31.2M
30 Jun 2023–-$3.5M
31 Mar 2023–-$14.5M
31 Dec 2022–-$10.3M
30 Sep 2022–-$8.6M
30 Jun 2022–-$9.2M
31 Mar 2022–-$8.8M
31 Dec 2021–-$6.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$110.6M -$46.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$26.9M -$27.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $18.3M $14.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $94.3M $48.1M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $76.0M $33.3M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Armata PharmaceuticalsARMP (this company) $112.7Mloss–––
Fate TherapeuticsFATE $111.8Mloss23.5-33%–
enGene TherapeuticsENGN $116.6Mloss–––
InvivydIVVD $122.0Mloss2.0+21%-215%
HumacyteHUMA $123.7Mloss51.6+53%–
Compass TherapeuticsCMPX $123.9Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+17%

62 13F filers vs 53

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

15%

5.6M shares held by 13F filers (30 Sep 2026) of 37.2M outstanding (6 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.5%

913K shares sold short (30 Oct 2026) of 37.2M outstanding (6 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.8

913K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.4%

900K shares sold short in the report before, 913K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

60%

60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

2

2 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

2 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 963K, 35× a year earlier

Price $3.03 on 20 Nov 2026, -58% over 12 months (12-month range $2.66 to $14.80)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
Capital spending per quarter. Capital spending $91K in the latest quarter, -62% on a year earlier.
Institutional holders (13F filers). 62 13F filers reported holding it in the latest 13F quarter, +138% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
27 Oct 2026Sharp changeShort interest spike: short interest spike, 900K vs usual 260K (2026-10-15); 40.9x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 964K vs usual 237K (2026-09-30); 40.2x the same period a year earlier
29 Sep 2026Sharp changeShort interest spike: short interest spike, 963K vs usual 228K (2026-09-15); 34.5x the same period a year earlier
15 Sep 2026Sharp changeShort interest spike: short interest spike, 885K vs usual 224K (2026-08-31); 24.1x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 835K vs usual 216K (2026-08-14); 16.9x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 856K vs usual 208K (2026-07-31); 17.0x the same period a year earlier
20 Jul 20268-K and other filingsDirector or officer change
27 Apr 20268-K and other filingsDirector or officer change
27 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Dec 20248-K and other filingsDirector or officer change
15 Nov 20248-K and other filingsDirector or officer change
3 Oct 20248-K and other filingsDirector or officer change
26 Sep 20248-K and other filingsDirector or officer change
15 Aug 20248-K and other filingsDirector or officer change
25 Jul 20248-K and other filingsDirector or officer change
25 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Sep 20238-K and other filingsDirector or officer change
19 Jul 20238-K and other filingsDirector or officer change
11 Jul 20238-K and other filingsDirector or officer change
5 May 20238-K and other filingsDirector or officer change
5 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Dec 20228-K and other filingsDirector or officer change
19 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Mar 20228-K and other filingsDirector or officer change
28 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2022: $18.1M published
Month from 1 Apr 2022: $26.9M published
Capital spending per quarter
Quarter ended 31 Dec 2021: $228K, -38% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $236K, -21% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $1.1M, +480% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $1.3M, +122% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $2.0M, +752% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $222K, -80% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $3.5M, +171% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $2.4M; public on 22 Mar 2024
Quarter ended 31 Mar 2024: $250K, -88% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $1.4M, +515% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $340K, -90% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Mar 2025: $99K, -60% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $149K, -89% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $242K, -29% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $52K; public on 26 Mar 2026
Quarter ended 31 Mar 2026: $63K, -36% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $17K, -89% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $91K, -62% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 17; public on 14 Feb 2022
31 Mar 2022 report: 20; public on 16 May 2022
30 Jun 2022 report: 17; public on 15 Aug 2022
30 Sep 2022 report: 19; public on 14 Nov 2022
31 Dec 2022 report: 23; public on 14 Feb 2023
31 Mar 2023 report: 23; public on 15 May 2023
30 Jun 2023 report: 20; public on 14 Aug 2023
30 Sep 2023 report: 20; public on 14 Nov 2023
31 Dec 2023 report: 24; public on 14 Feb 2024
31 Mar 2024 report: 24; public on 15 May 2024
30 Jun 2024 report: 20; public on 14 Aug 2024
30 Sep 2024 report: 23; public on 14 Nov 2024
31 Dec 2024 report: 23; public on 14 Feb 2025
31 Mar 2025 report: 25; public on 15 May 2025
30 Jun 2025 report: 25; public on 14 Aug 2025
30 Sep 2025 report: 26; public on 14 Nov 2025
31 Dec 2025 report: 36; public on 17 Feb 2026
31 Mar 2026 report: 44; public on 15 May 2026
30 Jun 2026 report: 53; public on 14 Aug 2026
30 Sep 2026 report: 62; public on 16 Nov 2026
Federal obligations
Month from 1 Apr 2023: $59K published

What is unusual now

  • Made public in the last 90 days: it had 963K shares sold short in the 15 Sep 2026 report, 35× the same report last year; it also had 964K shares sold short in the 30 Sep 2026 report, 40× the same report last year. 5 sharp changes in all.
  • Short interest spike: had 963K shares sold short in the 15 Sep 2026 report, 35× the same report last year Public on 25 Sep 2026.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • Capital spending per quarter: Capital spending $91K in the latest quarter, -62% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 10 insider trades

No trades in the last 90 days; the latest was filed 1 Apr 2022. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
1 Apr 2022Innoviva, Inc. and 1 otherDirector, 10% ownerBuy5,385,208$5.00$26.9MForm 4
11 Feb 2022Innoviva Strategic Opportunities LLC and 1 otherDirector, 10% ownerBuy3,614,792$5.00$18.1MForm 4
1 Nov 2021Innoviva Strategic Opportunities LLC and 1 otherDirector, 10% ownerBuy1,212,122$3.30$4.0MForm 4
17 Mar 2021Innoviva, Inc. and 1 otherDirector, 10% ownerBuy4,285,935$3.25$13.9MForm 4
28 Jan 2021Innoviva Strategic Opportunities LLC and 1 otherDirector, 10% ownerBuy1,867,912$3.25$6.1MForm 4
31 Mar 2020Innoviva, Inc.10% ownerBuy7,717,661$2.87$22.1MForm 4
29 Dec 2016Randal J Kirk and 1 other10% ownerSell177,020$0.48$84KForm 4

62 institutions reported shares at the end of Q3 2026, 15% of the shares outstanding; 12 opened a position, 3 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Madison Asset Management, LLC2.1M5.67%$7.7MNo change
Millennium Management LLC1.1M2.83%$3.9M+584K+124%
BlackRock, Inc.558K1.50%$2.0M-1,760-0.3%
Vanguard Capital Management LLC488K1.31%$1.8MNo change
Geode Capital Management, LLC279K0.75%$1.0M+7,994+3.0%
State Street Corp185K0.50%$677K+55K+42%
Grey Ledge Advisors, LLC100K0.27%$367K+50K+100%
Northern Trust Corp91K0.24%$332K+780+0.9%
Vanguard Portfolio Management LLC82K0.22%$299K+225+0.3%
Edgewood Management LLC80K0.22%$294KNo change

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 15 Sep 2008. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
15 Sep 2008Department of DefenseDepartment of the Army$2.4MPRECLINICAL DEVELOPMENT OF THERAPEUTICS FOR AMYOTROPHIC LATERAL SCLEROSISGrantUSAspending

Company events

All 71 company events

In 12 months: 3 major agreements, 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Jul 2026Director or officer change8-K
13 May 2026Signed a major agreementSame filing: took on new debt8-K
27 Apr 2026Director or officer change8-K
26 Jan 2026Signed a major agreement8-K
1 Dec 2025Signed a major agreement8-K
12 Aug 2025Signed a major agreementSame filing: took on new debt8-K
12 Mar 2025Signed a major agreementSame filing: took on new debt8-K
4 Dec 2024Director or officer change8-K

The 5 newest of 49 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 27 Oct 2026Short interest and volume change

    had 900K shares sold short in the 15 Oct 2026 report, 41× the same report last year.

    Same report last year: 22K; its normal report is 260K.

    See the evidence
    This period
    900K (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    260K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +4.0
    Same report last year
    22K
    History used
    2,710 days
    2025-10-15: 22K2025-10-31: 31K2025-11-14: 157K2025-11-28: 131K2025-12-15: 134K2025-12-31: 144K2026-01-15: 222K2026-01-30: 275K2026-02-13: 298K2026-02-27: 298K2026-03-13: 311K2026-03-31: 298K2026-04-15: 244K2026-04-30: 230K2026-05-15: 225K2026-05-29: 209K2026-06-15: 207K2026-06-30: 441K2026-07-15: 705K2026-07-31: 856K2026-08-14: 835K2026-08-31: 885K2026-09-15: 963K2026-09-30: 964K2026-10-15: 900K
    the 15 Oct 2026 report24 earlier reportsnormal: 260K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 10 Oct 2026Short interest and volume change

    had 964K shares sold short in the 30 Sep 2026 report, 40× the same report last year.

    Same report last year: 24K; its normal report is 237K.

    See the evidence
    This period
    964K (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    237K
    Typical spread (median absolute deviation)
    86K
    How far from its usual level
    +5.7
    Same report last year
    24K
    History used
    2,695 days
    2025-09-30: 24K2025-10-15: 22K2025-10-31: 31K2025-11-14: 157K2025-11-28: 131K2025-12-15: 134K2025-12-31: 144K2026-01-15: 222K2026-01-30: 275K2026-02-13: 298K2026-02-27: 298K2026-03-13: 311K2026-03-31: 298K2026-04-15: 244K2026-04-30: 230K2026-05-15: 225K2026-05-29: 209K2026-06-15: 207K2026-06-30: 441K2026-07-15: 705K2026-07-31: 856K2026-08-14: 835K2026-08-31: 885K2026-09-15: 963K2026-09-30: 964K
    the 30 Sep 2026 report24 earlier reportsnormal: 237K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 25 Sep 2026Short interest and volume change

    had 963K shares sold short in the 15 Sep 2026 report, 35× the same report last year.

    Same report last year: 28K; its normal report is 228K.

    See the evidence
    This period
    963K (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    228K
    Typical spread (median absolute deviation)
    83K
    How far from its usual level
    +6.0
    Same report last year
    28K
    History used
    2,680 days
    2025-09-15: 28K2025-09-30: 24K2025-10-15: 22K2025-10-31: 31K2025-11-14: 157K2025-11-28: 131K2025-12-15: 134K2025-12-31: 144K2026-01-15: 222K2026-01-30: 275K2026-02-13: 298K2026-02-27: 298K2026-03-13: 311K2026-03-31: 298K2026-04-15: 244K2026-04-30: 230K2026-05-15: 225K2026-05-29: 209K2026-06-15: 207K2026-06-30: 441K2026-07-15: 705K2026-07-31: 856K2026-08-14: 835K2026-08-31: 885K2026-09-15: 963K
    the 15 Sep 2026 report24 earlier reportsnormal: 228K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 11 Sep 2026Short interest and volume change

    had 885K shares sold short in the 31 Aug 2026 report, 24× the same report last year.

    Same report last year: 37K; its normal report is 224K.

    See the evidence
    This period
    885K (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    224K
    Typical spread (median absolute deviation)
    83K
    How far from its usual level
    +5.4
    Same report last year
    37K
    History used
    2,665 days
    2025-08-29: 37K2025-09-15: 28K2025-09-30: 24K2025-10-15: 22K2025-10-31: 31K2025-11-14: 157K2025-11-28: 131K2025-12-15: 134K2025-12-31: 144K2026-01-15: 222K2026-01-30: 275K2026-02-13: 298K2026-02-27: 298K2026-03-13: 311K2026-03-31: 298K2026-04-15: 244K2026-04-30: 230K2026-05-15: 225K2026-05-29: 209K2026-06-15: 207K2026-06-30: 441K2026-07-15: 705K2026-07-31: 856K2026-08-14: 835K2026-08-31: 885K
    the 31 Aug 2026 report24 earlier reportsnormal: 224K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 26 Aug 2026Short interest and volume change

    had 835K shares sold short in the 14 Aug 2026 report, 17× the same report last year.

    Same report last year: 50K; its normal report is 216K.

    See the evidence
    This period
    835K (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    216K
    Typical spread (median absolute deviation)
    83K
    How far from its usual level
    +5.1
    Same report last year
    50K
    History used
    2,648 days
    2025-08-15: 50K2025-08-29: 37K2025-09-15: 28K2025-09-30: 24K2025-10-15: 22K2025-10-31: 31K2025-11-14: 157K2025-11-28: 131K2025-12-15: 134K2025-12-31: 144K2026-01-15: 222K2026-01-30: 275K2026-02-13: 298K2026-02-27: 298K2026-03-13: 311K2026-03-31: 298K2026-04-15: 244K2026-04-30: 230K2026-05-15: 225K2026-05-29: 209K2026-06-15: 207K2026-06-30: 441K2026-07-15: 705K2026-07-31: 856K2026-08-14: 835K
    the 14 Aug 2026 report24 earlier reportsnormal: 216K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 12 Aug 2026Short interest and volume change

    had 856K shares sold short in the 31 Jul 2026 report, 17× the same report last year.

    Same report last year: 50K; its normal report is 208K.

    See the evidence
    This period
    856K (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    208K
    Typical spread (median absolute deviation)
    90K
    How far from its usual level
    +4.9
    Same report last year
    50K
    History used
    2,634 days
    2025-07-31: 50K2025-08-15: 50K2025-08-29: 37K2025-09-15: 28K2025-09-30: 24K2025-10-15: 22K2025-10-31: 31K2025-11-14: 157K2025-11-28: 131K2025-12-15: 134K2025-12-31: 144K2026-01-15: 222K2026-01-30: 275K2026-02-13: 298K2026-02-27: 298K2026-03-13: 311K2026-03-31: 298K2026-04-15: 244K2026-04-30: 230K2026-05-15: 225K2026-05-29: 209K2026-06-15: 207K2026-06-30: 441K2026-07-15: 705K2026-07-31: 856K
    the 31 Jul 2026 report24 earlier reportsnormal: 208K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 20 Jul 2026Filings record

    Director or officer change

  8. 27 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 27 Apr 2026Filings record

    Director or officer change

  10. 4 Dec 2024Filings record

    Director or officer change

  11. 15 Nov 2024Filings record

    Director or officer change

  12. 3 Oct 2024Filings record

    Director or officer change

  13. 26 Sep 2024Filings record

    Director or officer change

  14. 15 Aug 2024Filings record

    Director or officer change

  15. 25 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 25 Jul 2024Filings record

    Director or officer change

  17. 20 Sep 2023Filings record

    Director or officer change

  18. 19 Jul 2023Filings record

    Director or officer change

  19. 11 Jul 2023Filings record

    Director or officer change

  20. 5 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 5 May 2023Filings record

    Director or officer change

  22. 19 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 19 Dec 2022Filings record

    Director or officer change

  24. 2 Apr 2022Insiders record

    Innoviva, Inc. (director) and 1 other(s) bought 5,385,208 shares of ARMP ($26.9M) (dated 1 Apr 2022)

  25. 28 Mar 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 28 Mar 2022Filings record

    Director or officer change

  27. 12 Feb 2022Insiders record

    Innoviva Strategic Opportunities LLC (director) and 1 other(s) bought 3,614,792 shares of ARMP ($18.1M) (dated 11 Feb 2022)

  28. 2 Nov 2021Insiders record

    Innoviva Strategic Opportunities LLC (director) and 1 other(s) bought 1,212,122 shares of ARMP ($4.0M) (dated 1 Nov 2021)

  29. 4 Aug 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 4 Aug 2021Filings record

    Director or officer change

  31. 5 Apr 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 5 Apr 2021Filings record

    Director or officer change

  33. 18 Mar 2021Insiders record

    Innoviva, Inc. (director) and 1 other(s) bought 4,285,935 shares of ARMP ($13.9M) (dated 17 Mar 2021)

  34. 29 Jan 2021Insiders record

    Innoviva Strategic Opportunities LLC (director) and 1 other(s) bought 1,867,912 shares of ARMP ($6.1M) (dated 28 Jan 2021)

  35. 1 Apr 2020Insiders record

    Innoviva, Inc. (ten percent owner) bought 7,717,661 shares of ARMP ($22.1M) (dated 31 Mar 2020)

  36. 13 Feb 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 13 Feb 2020Filings record

    Director or officer change

  38. 9 Jan 2020Filings record

    Registered new securities for sale (S-1) (dated 8 Jan 2020)

  39. 20 Dec 2019Filings record

    Registered new securities for sale (S-1)

  40. 10 Oct 2019Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 76 entries; narrow the window or the kind of data to see older ones.

Not listed: 147 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000921114
Ticker
ARMP
Domain
armatapharma.com
Hq location
CA|LOS ANGELES|90066 (1 unverified)
Name
AmpliPhi Biosciences Corp, Armata Pharmaceuticals, Inc., TARGETED GENETICS CORP /WA/
Uei
WLFUPWSDLNQ4
  • SEC Form 13F institutional holdings279 data points31 Mar 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)195 records8 Jan 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)696 data points31 Dec 2012 to 6 Nov 2026
  • SEC Form 4 insider transactions10 records, 36 data points12 Apr 2016 to 1 Apr 2022
  • FINRA short interest (twice monthly)537 data points15 May 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3780 data points10 May 2019 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 21 data points15 Sep 2008 to 9 Mar 2023